Medical expenditures for fragility hip fracture in Japan: a study using the nationwide health insurance claims database

Takahiro Mori1,2,3 · Jun Komiyama4 · Tomoko Fujii1,5 · Masaru Sanuki6 · Keitaro Kume6 · Genta Kato7 · Yukiko Mori8 · Hiroaki Ueshima8 · Hiroki Matsui9 · Nanako Tamiya1,10 · Takehiro Sugiyama1,10,11

Received: 29 December 2021 / Accepted: 9 March 2022 / Published online: 11 April 2022 © The Author(s) 2022

Abstract
Summary Using the nationwide health insurance claims database in Japan, we estimated total annual medical expenditures for fragility hip fracture across the population at 329.2 billion yen (2.99 billion US dollars). Long-term care expenditures were not included. Fragility hip fracture imposes a considerable health economic burden on society in Japan.
Purpose Fragility hip fracture imposes a substantial health economic burden on society globally. We aimed to estimate medical expenditures for fragility hip fracture using the nationwide health insurance claims database in Japan.
Methods We included adults aged 60 and over without prior hip fracture who were admitted for fragility hip fracture (i.e., femoral neck or extracapsular) between October 2014 and October 2015 (13 months). Fragility hip fracture was identified through newly assigned disease codes for fracture and procedure codes associated with the fracture. As a proxy for medical expenditures per patient, incremental payments were calculated (i.e., the difference between the total payments 6 months before and after fragility hip fracture). The total payments included health insurance reimbursements and copayments for inpatient and outpatient services. Long-term care expenditures were not included in this study.
Results We identified 142,361 individuals (28,868 male and 113,493 female) with fragility hip fracture. Mean medical expenditures for fragility hip fracture per patient were 2,550,000 yen (¥) (23,180 US dollars [$]; ¥110 = $1) in male and ¥2,494,000 ($22,670) in female patients, respectively. Total annual medical expenditures for fragility hip fracture across the population were 329.2 billion yen (2.99 billion US dollars): 67.96 billion yen (620 million US dollars) in male and 261.24 billion yen (2.37 billion US dollars) in female patients, respectively.
Conclusion This is the first study to estimate medical expenditures for hip fracture using the nationwide health insurance claims database, which represents almost all health insurance claims in Japan. Fragility hip fracture inflicts a considerable health economic burden on society in Japan.

Keywords Medical expenditures · Hip fracture · National Database of Health Insurance Claims and Specific Health Checkups of Japan · Osteoporosis

Introduction
Fragility hip fracture imposes a substantial health economic burden on society at large. A systematic review and meta-regression analysis, which included 113 studies of over 670,000 patients between 1990 and 2015 [1], has reported a health economic burden inflicted by fragility hip fracture worldwide. The study reported that the pooled mean costs of total health and social care per patient in the 12 months following hip fracture were estimated to be higher than the counterpart estimates for acute coronary syndrome or ischemic stroke. Although the systematic review and meta-regression analysis included studies mainly conducted in North America and Western Europe (44% and 35%, respectively), the authors pointed out that medical expenditures post–hip fracture differ across regions [1]. Three studies in Japan were included in the abovementioned systematic review and meta-regression analysis [2–4]. However, the generalizability of these studies was restricted, as the numbers of hip fracture patients in these three respective studies were only 778 in ten hospitals, 813 in seven hospitals, and 148 in three hospitals. Since 2016, two studies...
have been conducted on medical expenditures post–hip fracture in Japan using health insurance claims data [5, 6]. In a smaller-scale study published in 2018 using merged health and long-term care insurance claims data from one city (Kashiwa, in Chiba prefecture) to estimate medical expenditures, the number of patients with hip fracture was only 78 [5]. Another study, published in 2018 and using health insurance claims data, included 2415 patients with hip fracture at more than 240 acute care hospitals. Although this was a larger-scale study covering almost one-eighth of the population in Japan, the authors still suggested the possibility of selection bias as one of the limitations of the study (Supplemental Table 1) [6].

To the best of our knowledge, however, no national-level study has been conducted on medical expenditures post–hip fracture in Japan. Using the nationwide health insurance claims database, we aimed to estimate not only mean medical expenditures for fragility hip fracture per patient but also total medical expenditures for fragility hip fracture across the population in Japan.

Methods

Data source

In Japan, the universal health insurance system was first implemented in 1961. Since 2008, the copayments have been 30% for adults aged under 70 years, 20% or 30% for those aged between 70 and 74 years, and 10% or 30% for those aged over 75 years [7]. The National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB) is a national database of health insurance claims and specific health checkup data, and provides all information on universal health insurance, including age, sex, diseases/conditions, diagnostic examinations, medical treatments, surgical procedures, and prescribed medications. The NDB represents almost all health insurance claims in Japan, as Japan has universal health coverage with some exceptions such as accidents covered by automobile liability insurance or workers’ accident compensation outside of the universal health insurance. In addition, local governments provide payments for those on public welfare (less than 2% of the population) [8–16]. We obtained individual-level NDB data for those who met the International Statistical Classification of Diseases and Related Health Problems 10th revision’s (ICD-10’s) criteria for hip fractures (S72, M8435, M8445, M8005, M8085, or M8095) between April 2014 and September 2016. As a personal identification variable, we used ID0 in this analysis [17]. The NDB did not provide the data for the disease codes or procedure codes that had less than 1000 cases per year; however, this did not affect the total payments for each individual. Subject to restrictions, the NDB data may be obtained from the Japanese Ministry of Health, Labour, and Welfare.

Study population

We included adults aged 60 years and older without prior hip fracture including not only fragility but also open or stress hip fracture (no disease codes for such hip fractures were assigned between April 2014 and September 2014) and who were admitted for new fragility hip fracture between October 2014 and October 2015 (13 months). We chose the period between October 2014 and October 2015 to ensure sufficient pre– and post–hip fracture durations (6 months for each) as described below in the measurements section. We excluded those with less than 6 months of pre–hip fracture duration. In contrast, we included those who died within 6 months post–hip fracture in the base case.

We identified new fragility hip fracture by newly assigned disease codes of hip fracture, including femoral neck and extracapsular (inter- and subtrochanteric), and the surgical procedure codes associated with hip fracture, including total hip replacement, bipolar hip arthroplasty, open or closed reduction and internal fixation, and conservative management (Supplemental Table 2) [5, 13]. We used disease codes instead of ICD-10 codes because disease codes provided more detailed information regarding diagnoses. A study in Japan reported that approximately 98% of patients with hip fracture underwent surgical procedures within 16 days of admission, including the day of admission [18]. Therefore, we excluded those who underwent surgical procedures for hip fracture after 17 days of admission, as it was likely that they were admitted for a different reason and subsequently suffered from hip fracture during hospitalization.

Measurements

To estimate mean medical expenditures for fragility hip fracture per patient, we used incremental payments as a proxy of medical expenditures; they were calculated as the difference between the total payments 6 months before (i.e., including the month prior to admission for hip fracture and backward) and 6 months after hip fracture (i.e., including the month of admission for hip fracture and forward). We adopted Kilgore et al.’s method, in which the difference between medical expenditures 6 months pre- and post-fracture was calculated on the same individual among the Medicare beneficiaries in the US [19]. In the current study, the total payments consisted of both national health insurance reimbursements and copayments for inpatient and outpatient services. Inpatient services
were provided at Diagnosis Procedure Combination/Per-Diem Payment System (DPC/PDPS) and non-DPC/PDPS hospitals. In DPC/PDPS hospitals, two payment systems (i.e., a flat-fee per-diem payment according to diagnostic categories and a fee-for-service payment according to procedures) are incorporated for acute inpatient services. In non-DPC/PDPS hospitals, only a fee-for-service payment system is used [5]. The fee for inpatient prescriptions was included in the inpatient payments. The payments for outpatient services include fees charged by the medical facility and pharmacy. We did not include payments for dental services, meals, living during hospitalization, home nursing care, prosthetic devices, judo therapist, massage, acupuncture, or moxibustion. In Japan, long-term care insurance is separated from health insurance, and long-term care expenditures were not included in this analysis. Outpatient rehabilitation/physiotherapy services are covered either through health insurance or long-term care insurance. We have presented the main payments between April 2014 and March 2016 (fiscal years 2014 and 2015) in Japanese yen (¥). For ease of interpretation, we converted them to US dollars [$] at a rate of ¥110 to $1, which is the approximate mean annual exchange rates between 2014 and 2020 [20].

In addition to the disease codes and surgical procedure codes, we used age (stratified by 5-year ranges as of April 2014), sex, and location of the hospital/clinic (i.e., 47 prefectures, which are official geographical regions in Japan). As a proxy for multimorbidity, we obtained the 2011 updated version of the Charlson Comorbidity Index (CCI) scores by using disease codes within 6 months of admission for hip fracture including the month of admission [21]. We excluded the data in which the diagnoses were provided with a “suspicous” flag, suggesting that tentative diagnoses were placed for the purpose of justifying diagnostic examinations.

Analysis

In the base case, we calculated mean and median medical expenditures for fragility hip fracture per patient, stratified by sex and including both sexes. Then, we calculated annual medical expenditures for fragility hip fracture across the population by multiplying the number of fractures by mean medical expenditures per patient. As our study population was those who were admitted for new fragility hip fracture over 13 months (i.e., between October 2014 and October 2015), we made an adjustment to obtain annual medical expenditures (i.e., 12 months). In addition, we calculated mean medical expenditures per patient, stratified by age range, anatomical sites of fracture, and surgical procedures. If the disease codes of the hip fractures of multiple anatomical sites were identified, the priority of the classification was the femoral neck followed by extracapsular fractures. If multiple surgical procedures were identified, the priority of the classification was total hip replacement, bipolar hip arthroplasty, open or closed reduction and internal fixation, followed by conservative management. Next, we calculated mean medical expenditures per patient stratified by 47 prefectures in Japan to examine regional differences in Japan. Finally, as a sensitivity analysis, we calculated mean and median medical expenditures, excluding those who died within 6 months after hip fracture including the month of admission for hip fracture. Death was confirmed by the outcomes of inpatient or outpatient services or by the surcharges of the death certificate or end-of-life care. A previous validation study in Japan regarding the accuracy of death information in health insurance claims data showed that claims data can be useful in identifying death, especially inpatient death [22].

Results

Between October 2014 and October 2015, 142,361 individuals (28,868 male and 113,493 female) were admitted for fragility hip fracture. Among those 48.2% male and 49.6% female patients fell within the age range 80–89 (i.e., the sum of 80–84 and 85–89) (Fig. 1). Femoral neck and extracapsular fractures accounted for 58.0% and 42.0%, respectively, in male patients and 56.1% and 43.9%, respectively, in female patients. For femoral neck fracture, bipolar hip arthroplasty was the most common procedure (59.8% in male and 58.9% in female patients), followed by open or closed reduction and internal fixation (33.2% male and 35.1% in female patients). For extracapsular fracture, open or closed reduction and internal fixation were by far the most common procedures (95.2% in male and 95.7% in female patients) (Supplemental Fig. 1). The mean CCI scores were 3.17 in male and 2.56 in female (Supplemental Fig. 2).

Mean and median medical expenditures for fragility hip fracture per patient were ¥2,550,000 ($23,180) and ¥2,369,000 ($21,540) in male and ¥2,494,000 ($22,670) and ¥2,310,000 ($21,000) in female patients, respectively (Table 1; Supplemental Fig. 3). Including both sexes, the mean and median expenditures per patient were ¥2,505,000 ($22,700) and ¥2,321,000 ($21,100), respectively. Total annual medical expenditures for fragility hip fracture across the population were 329.2 billion yen (2.99 billion US dollars): 67.96 billion yen (620 million US dollars) in male and 261.24 billion yen (2.37 billion US dollars) in female patients, respectively.

Mean medical expenditures per patient were highest in the age range of 80–84 in both sexes (Fig. 2; Supplemental Table 3). For femoral neck fracture, mean medical expenditures per patient were higher in those with bipolar hip
Fig. 1 Fragility hip fracture reported between October 2014 and October 2015 (13 months), stratified by age range. a) Male \( (n=28,868) \), b) Female \( (n=113,493) \)

### Table 1
Mean medical expenditures for fragility hip fracture per patient: unit 10,000 yen (US dollars [$], 110 yen = $1)

|                      | Male \( (n=28,868) \) |           | Female \( (n=113,493) \) |           |
|----------------------|------------------------|-----------|---------------------------|-----------|
|                      | Mean                   | Median    | Mean                      | Median    |
| Total                | 255.0 ($23,180)        | 236.9 ($21,540) | 249.4 ($22,670)        | 231.0 ($21,000) |
| Inpatient            | 266.8 ($24,260)        | 246.4 ($22,400) | 256.8 ($23,340)        | 236.7 ($21,520) |
| Outpatient (medical facility) | −7.6 (−690) | −2.1 (−190) | −4.1 (−380) | −1.5 (−130) |
| Outpatient (pharmacy) | −4.2 (−380) | −1.6 (−140) | −3.2 (−290) | −1.3 (−120) |
arthroplasty than in those with open or closed reduction and internal fixation (¥2,885,000 [$26,230] and ¥2,227,000 [$20,240] in male, ¥2,804,000 [$25,490] and ¥2,187,000 [$19,880] in female patients, respectively). For extracapsular fracture, mean medical expenditures per patient for those with open or closed reduction and internal fixation were ¥2,444,000 ($22,220) in male and ¥2,399,000 ($21,810) in female patients, respectively (Supplemental Table 4). Finally, mean medical expenditures differed across the prefectures, with ¥2,991,000 ($27,190) being the highest and ¥2,088,000 ($18,990) being the lowest in male and ¥3,023,000 ($27,490) being the highest and ¥2,087,000 ($18,980) being the lowest in female patients (Supplemental Fig. 4). In a sensitivity analysis, in which we excluded those who died within 6 months post–hip fracture (11.5% in male and 5.0% in female patients), mean and median medical expenditures per patient were almost the
same as those in the primary analysis in both sexes (Supplemental Table 5).

**Discussion**

Using the NDB database, which represents almost all health insurance claims in Japan, we estimated medical expenditures for fragility hip fracture in 142,361 individuals (28,868 male and 113,493 female). Total annual medical expenditures for fragility hip fracture across the population were 329.2 billion yen (2.99 billion US dollars): 67.96 billion yen (620 million US dollars) in male and 261.24 billion yen (2.37 billion US dollars) in female patients, respectively.

We used incremental payments as a proxy for mean medical expenditures for fragility hip fracture per patient; they were calculated as the difference between the total payments 6 months before and 6 months after hip fracture. The main advantage of this approach is that the pre-fracture condition of an individual is considered to be a control for the post-fracture condition of the same individual [5, 19]. The incremental differences in the total payments are considered to be dependable estimations of the avoidable costs associated with fracture than the alternatives, such as the summation of all the costs after a fracture or comparison of the costs between the fracture cases and controls [23]. The payments were provided on a monthly basis. Our approach may have resulted in the underestimation of the payments after hip fracture, because we could not take into account the dates of admission for hip fracture. For example, whether an individual was admitted on October 1 or on October 31, the payment in October was considered post–hip fracture in either case. We, however, did not consider this to be a major issue, as 6 months before and after hip fracture are enough durations to capture medical payments post–hip fracture covered by health insurance.

Since 2010, 14 cost-effectiveness analysis articles that included the costs of hip fracture in the Japanese setting have been published (Supplemental Table 6) [24–37]. Among them, nine were published between 2011 and 2019, which cited Kondo et al.’s article published in 2009 as a reference for the cost of hip fracture [4]. Since 2020, five cost-effectiveness analysis articles have been published. Regarding the costs of hip fracture, Taguchi et al.’s article was cited three times and Mori et al.’s article was cited once; both the articles were published in 2018. A cost-effectiveness analysis article written in Japanese cited Ota’s article (also written in Japanese) published in 2002 [5, 6, 38]. Ishizaki et al., Hirose et al., and Kondo et al.’s studies, published before 2009, summed up all the costs after fracture, while Taguchi et al. and Mori et al.’s studies calculated the incremental differences in the total payments before and after hip fracture [2–6]. (Supplemental Table 1).

Our results were very similar to those of a previous study by Mori et al. (coauthored by a few authors of the current study) using health insurance claims data in the city of Kashiiwa, the population of which was approximately 400,000 in 2012, located in Chiba prefecture. In this study, the target population was adults aged 75 years and over admitted for hip fracture to non-DPC/PDPS hospitals between April 2012 and September 2013. Mean medical expenditures per patient were calculated using almost the same method as that used in the current study (i.e., the difference between the total payments 6 months before and after hip fracture of the same individuals). The study included only 78 individuals and showed that estimated mean medical expenditures per patient were ¥2,600,000 or $29,500 (¥88 = $1) [5]. With the availability of the NBD database that represents almost all health insurance claims in Japan, the present study confirmed the generalizability of the results of the previous study in a single city. In addition, we estimated total annual medical expenditures for fragility hip fracture across the population in Japan.

Mean medical expenditures for fragility hip fracture per patient were the highest in the age range of 80–84 in both sexes in our study. These results were not consistent with total annual mean medical expenditures for any diseases or conditions per patient in Japan in the fiscal year 2015, in which total annual mean medical expenditures (i.e., the sum of inpatient and outpatient medical services and pharmacy) per patient for those aged 85 years and over were higher (¥1,100,000 or $10,000 in male and ¥954,000 or $8670 in female) than for those aged between 80 and 84 years (¥965,000 or $8770 in male and ¥810,000 or $7360 in female) [39]. These results may be owing to the fact that invasive procedures and treatments may be withheld for those with hip fracture aged 85 and over, and especially for those aged beyond 90. A previous study in ten teaching hospitals in Japan between 1996 and 2000 showed that mean medical expenditures post–hip fracture per patient was $15,012 or ¥1,801,000 ($1 = ¥120) in individuals aged 65–74 years (n = 190), $14,744 or ¥1,769,000 in individuals aged 75–84 years (n = 356), and $13,690 or ¥1,643,000 in individuals aged 85 years and over (n = 232) (p-value of Kruskal–Wallis test: 0.006). These findings were consistent with ours that mean medical expenditures for those aged 85 years and over were not higher than expenditures for those aged between 75 and 84 years, but not consistent with our finding that expenditures for those aged between 65 and 74 years were higher than expenditures for those aged between 75 and 84 years [2]. However, it is difficult to interpret the results, comparing our study with the study that used the data between 1996 and 2000.

For femoral neck fracture, bipolar hip arthroplasty was the most common procedure, followed by open or closed
reduction and internal fixation. Mean medical expenditures for hip fracture per patient were higher in those with bipolar hip arthroplasty (¥2,885,000 [$26,230] in male and ¥2,804,000 [$25,490] in female patients) than in those with open or closed reduction and internal fixation (¥2,227,000 [$20,240] in male and ¥2,187,000 [$19,880] in female patients) (Supplemental Table 4). The payments for the procedures, including both reimbursements and copayments, were ¥195,000 ($1,770) for bipolar hip arthroplasty and ¥188,000 ($1,710) for open or closed reduction and internal fixation during the study period (i.e., the fiscal year 2014–2015); the difference in the payments (¥7000, or $70) was not enough to explain the difference between the expenditures [40]. For extracapsular fracture, open or closed reduction and internal fixation were by far the most common procedures, and mean medical expenditures per patient for those with open or closed reduction and internal fixation were ¥2,444,000 ($22,220) in male and ¥2,399,000 ($21,810) in female patients. Mean medical expenditures per patient for open or closed reduction and internal fixation were higher for those with extracapsular fracture than for those with femoral neck fracture.

Mean medical expenditures for hip fracture per patient in each prefecture have been presented. Overall, there seem to be a similar trend in mean medical expenditures for fragility hip fracture per patient stratified by prefecture to the regional differences in total annual medical expenditures for any diseases or conditions per patient in Japan (i.e., higher expenditures in the western part of Japan than in the eastern part) [41].

Since 2019, several studies have reported osteoporotic fracture using the NDB database. One study examined the association between seasonality and incident fracture at different sites [8]. Using a case-crossover study design, incident fragility fracture, the associations of statin use with fragility fracture, and the associations of central nervous system agents with fragility fracture have been reported [9–12]. The studies examining the testing rates of bone mineral density and pharmacotherapy after hip or vertebral fracture and persistence to pharmacotherapy for osteoporosis have been presented [14, 15]. Aggregated NDB data have been used to examine the annual incidence rates of hip fracture [13, 16]. To the best of our knowledge, our study is the first health economic study regarding osteoporotic fracture using the NDB database in Japan, and it has revealed the status of medical expenditures for hip fracture in Japan.

This study has several limitations. First, health insurance claims data were not intended to be developed for research purposes; therefore, they are subject to coding errors and misclassifications. We have made great efforts to identify new fragility hip fracture by combining newly assigned disease codes of hip fracture and surgical procedures associated with hip fracture. Second, it is important to note that we only included direct costs post-fracture and that there are also considerable additional costs associated with social aspects of care. In Japan, long-term care insurance is separated from health insurance and covers social aspects of care to some extent. Using the NDB database, we calculated the differences between the total payments 6 months before and after hip fracture to estimate medical expenditures for hip fracture. Although long-term care plays a major role beyond 6 months post–hip fracture, we did not include long-term care expenditures in this study, as the NDB database provides information regarding health insurance but does not contain information regarding long-term care insurance [5]. Future studies are warranted when comprehensive data including both medical and long-term care expenditures post–hip fracture are available for academic use. Third, although we estimated total annual medical expenditures for fragility hip fracture across the population in Japan, it would be difficult to compare these expenditures with the annual expenditures for other diseases because of the lack of such counterpart studies (to the best of our knowledge) in Japan. Further studies will be warranted to reveal such expenditures using the NDB database. Finally, although we found several differences in medical expenditure post–hip fracture among groups, examining the factors associated with these differences was beyond the scope of this study.

Despite these limitations, our study had several strengths. This is the first study to estimate medical expenditures for hip fracture using the nationwide health insurance claims database, which represents almost all health insurance claims in Japan and estimated not only mean medical expenditures for fragility hip fracture per patient but also annual medical expenditures for fragility hip fracture across the population. In addition, we calculated mean medical expenditures for fragility hip fracture per patient stratified by sex and further by age range, anatomical sites and surgical procedures, and prefecture. Our results, especially sex- and age-range-stratified expenditures, may prove to be useful for future cost-effectiveness analyses in Japan, where the annual incidence rate of hip fracture has increased [42]. Cost-effectiveness analysis has become even more important in Japan, as in 2019, the Japanese Ministry of Health, Labour, and Welfare officially introduced health technology assessment by implementing cost-effectiveness analysis to determine price adjustments for drugs and medical devices [43].

In conclusion, using the NDB database representative of almost all health insurance claims in Japan, we estimated total annual medical expenditures for fragility hip fracture across the population at 329.2 billion yen (2.99 billion US dollars). Fragility hip fracture imposes a considerable health economic burden on society in Japan.

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1007/s11657-022-01096-8.
Author contribution  Takahiro Mori: conception and design, analysis and interpretation of data, drafting the article, revising the article critically for important intellectual content, and final approval. Takahiro Mori had full access to all of the data in the study and took responsibility for the integrity of the data and the accuracy of the data analysis.

Jun Komiyama: conception and design, analysis and interpretation of data, revising the article critically for important intellectual content, and final approval. Jun Komiyama had full access to all of the data in the study and took responsibility for the integrity of the data and the accuracy of the data analysis.

Tomoko Fujii: conception and design, interpretation of data, revising the article critically for important intellectual content, and final approval.

Masaru Sanuki: analysis of data, revising the article critically for important intellectual content, and final approval.

Keitaro Kume: analysis of data, revising the article critically for important intellectual content, and final approval.

Genta Kato: collection of data, revising the article critically for important intellectual content, and final approval.

Yukiko Mori: collection of data, revising the article critically for important intellectual content, and final approval.

Hiroaki Ueshima: collection of data, revising the article critically for important intellectual content, and final approval.

Hiroki Matsui: collection of data, revising the article critically for important intellectual content, and final approval.

Nanako Tamiya: collection of data, analysis of data, revising the article critically for important intellectual content, and final approval.

Takehiro Sugiyama: collection of data, interpretation of data, revising the article critically for important intellectual content, and final approval.

Funding  This work was mainly supported by a grant-in-aid from the Ministry of Health, Labour and Welfare Policy Research Grants, Japan (grant number: 21AA2006) and was also partially supported by JSPS KAKENHI Grant (grant number JP 20K10340).

Data availability  The data and material may be obtained from the Japanese Ministry of Health, Labour, and Welfare.

Code availability  Considered upon request.

Declarations

Ethics approval  The ethics committee of the University of Tsukuba approved this study (approval number: 1476).

Consent to participate  Not required.

Consent for publication  Not applicable.

Conflict of interest  None.

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Williamson S, Landeiro F, McConnell T, Fulford-Smith L, Javaid MK, Judge A, Leaf J (2017) Costs of fragility hip fractures globally: a systematic review and meta-regression analysis. Osteoporos Int 28(10):2791–2800. https://doi.org/10.1007/s00198-017-4153-6

2. Ishizaki T, Imanaka Y, Oh E, Kuwabara K, Hirose M, Hayashiwa K, Harada Y (2004) Association of hospital resource use with comorbidity status and patient age among hip fracture patients in Japan. Health Policy 69(2):179–187. https://doi.org/10.1016/j.healthpol.2003.12.018

3. Hirose J, Mizuta H, Ide J, Nakamura E, Takada K (2008) E-PASS for predicting postoperative risk with hip fracture: a multicenter study. Clin Orthop Relat Res 466(11):2833–2841. https://doi.org/10.1007/s11999-008-0377-2

4. Kondo A, Zierler BK, Isokawa Y, Hagino H, Ito Y (2009) Comparison of outcomes and costs after hip fracture surgery in three hospitals that have different care systems in Japan. Health Policy 91(2):204–210. https://doi.org/10.1016/j.healthpol.2008.12.006

5. Mori T, Tamiya N, Jin X, Jeon B, Yoshiie S, Iijima K, Ishizaki T (2018) Estimated expenditures for hip fractures using merged healthcare insurance data for individuals aged ≥75 years and long-term care insurance claims data in Japan. Arch Osteoporos 13(1):37. https://doi.org/10.1007/s11657-018-0448-2

6. Taguchi Y, Inoue Y, Kido T, Arai N (2018) Treatment costs and cost drivers among osteoporotic fracture patients in Japan: a retrospective database analysis. Arch Osteoporos 13(1):45. https://doi.org/10.1007/s11657-018-0456-2

7. Japanese Ministry of Health, Labour and Welfare (2020) Health and medical services. https://www.mhlw.go.jp/english/wp/wp-hlw13/dl02e.pdf. Accessed 28 Dec 2021

8. Hayashi S, Noda T, Kubo S, Myojin T, Nishioka Y, Higashino T, Imamura T (2019) Variation in fracture risk by season and weather: a comprehensive analysis across age and fracture site using a national database of health insurance claims in Japan. Bone 120:512–518. https://doi.org/10.1016/j.bone.2018.12.014

9. Iihara N, Ohara E, Baba K, Nagao S, Bando Y, Yoshida T, Ohara M, Kirino Y (2019) Decreased risk of fragility fractures associated with statin use in the older Japanese population: a nationwide case–crossover study. BPB Rep 2(3):35–38. https://doi.org/10.1248/bpbreports.2.3_35

10. Iihara N, Ohara E, Bando Y, Yoshida T, Ohara M, Kirino Y (2019) Fragility fractures in older people in Japan based on the national health insurance claims database. Bioll Pharm Bull 42(5):778–785. https://doi.org/10.1248/bpb.b18-00974

11. Ohara E, Bando Y, Yoshida T, Ohara M, Kirino Y, Iihara N (2020) Central nervous system agent classes and fragility fracture risk among elderly Japanese individuals in a nationwide case-crossover design study. Bioll Pharm Bull 43(2):340–347. https://doi.org/10.1248/bpb.b19-00737

12. Ohara E, Bando Y, Yoshida T, Ohara M, Kirino Y, Iihara N (2021) Fracture risk increased by concurrent use of central nervous system agents in older people: nationwide case-crossover study. Res Social Adrn Pharm 17(6):1181–1197. https://doi.org/10.1016/j.sapharm.2020.09.007
13. Tamaki J, Fujimori K, Ikehara S, Kamiya K, Nakatoh S, Okimoto N, Ogawa S, Ishii S, Iki M, Working Group of Japan Osteoporosis Foundation (2019) Estimates of hip fracture incidence in Japan using the National Health Insurance Claim Database in 2012–2015. Osteoporos Int 30(5):975–983. https://doi.org/10.1007/s00198-019-04844-8

14. Nakatoh S, Fujimori K, Ishii S, Tamaki J, Okimoto N, Ogawa S, Iki M (2021) Insufficient increase in bone mineral density testing rates and pharmacotherapy after hip and vertebral fracture: analysis of the National Database of Health Insurance Claims and Specific Health Checkups of Japan. Arch Osteoporos 16(1):130. https://doi.org/10.1007/s11657-021-00992-9

15. Nishioka M, Kim JI, Yoshiya K, Shin J, Hasegawa H, Taniguchi S, Komaba H, Moriwaki K, Fujimori A, Shibuya K, Morrisey MA (2013) A close examination of healthcare expenditure and patient-matching technique. BioRxiv. 280008 doi.org/10.1016/j.jbmr.2021.05.021

16. Fujii K, Ishijima M (2021) Cost-effectiveness of exercise programs designed for fall. Prevention among healthy younger older menopausal osteoporosis patients with previous hip fracture in Japan. Osteoporos Int 32(6):1939–1950. https://doi.org/10.1007/s00198-021-05927-1

17. Shinichiro K, Tatsuya N, Tomoya M, Yuichi N, Tsuneyuki H, Hiroki M, Genta K, Tomoaki I (2018) National database of health insurance claims and specific health checkups of Japan (NDB): outline and patient-matching technique. BioRxiv. 280008 doi.org/10.1016/j.jbmr.2021.05.021

18. Hayashi H, Endo N, Harada A, Iwamoto J, Mashiba T, Mori S, Ohtori S, Sakai A, Takada J, Yamamoto T (2017) Survey of hip fractures in Japan: recent trends in prevalence and treatment. J Orthop Sci 22(5):909–914. https://doi.org/10.1016/j.jos.2017.06.003

19. Kilgore ML, Morrissey MA, Becker DJ, Gary LC, Crandall CJ, Saag KG, Yun H, Matthews R, Smith W, Taylor A, Arora T, Delzella E (2009) Health care expenditures associated with skeletal fractures among Medicare beneficiaries, 1999–2005. J Bone Miner Res 24(12):2050–2055. https://doi.org/10.1359/jbmr.090523

20. X-RATES Currency calculator. http://www.x-rates.com. Accessed 28 Dec 2021

21. Mori T, Hamada S, Yoshie S, Jeon B, Jin X, Takahashi H, Iijima K, Ishizaki T, Tamiya N (2019) The associations of multimorbidity with the sum of annual medical and long-term care expenditures in Japan. BMC Geriatr 19(1):69. https://doi.org/10.1186/s12999-019-0189-9

22. Sakai M, Ohtera S, Iwao T, Neff Y, Kato G, Takahashi Y, Nakayama T, BiDAME (Big Data Analysis of Medical care for the Elderly in Kyoto) (2019) Validation of claims data to identify death among aged persons utilizing enrollment data from health insurance unions. Environ Health Prev Med 24(1):63. https://doi.org/10.1186/s12199-019-0189-9

23. Kilgore ML, Curtis JR, Delzell E, Becker DJ, Arora T, Saag KG, Morrissey MA (2013) A close examination of healthcare expenditures related to fractures. J Bone Miner Res 28(4):816–820. https://doi.org/10.1002/jbmr.1789

24. Goto S, Komaba H, Moriwaki K, Fujimori A, Shibuya K, Nishioka M, Kim JI, Yoshiya K, Shin J, Hasegawa H, Taniguchi M, Fujii H, Nishi S, Kamei I, Fukagawa M (2011) Clinical efficacy and cost-effectiveness of lanthanum carbonate as second-line therapy in hemodialysis patients in Japan. Clin J Am Soc Nephrol 6(6):1375–1384. https://doi.org/10.2215/CJN.08841010

25. Komaba H, Moriwaki K, Goto S, Yamada S, Taniguchi M, Kakuta T, Kamei I, Fukagawa M (2012) Cost-effectiveness of cinacalcet hydrochloride for hemodialysis patients with severe secondary hyperparathyroidism in Japan. Am J Kidney Dis 60(2):262–271. https://doi.org/10.1053/j.ajkd.2011.12.034

26. Moriwaki K, Komaba H, Noto S, Yanagisawa S, Takiguchi T, Inoue H, Toujo T, Fukagawa M, Takahashi HE (2013) Cost-effectiveness of alendronate for the treatment of osteoporotic postmenopausal women in Japan. J Bone Miner Res 28(2):395–403. https://doi.org/10.1002/jbmr.1755

27. Moriwaki K, Noto S (2017) Economic evaluation of osteoporosis liaison service for secondary fracture prevention in postmenopausal osteoporosis patients with previous hip fracture in Japan. Osteoporos Int 28(2):621–632. https://doi.org/10.1007/s00198-016-3777-2

28. Yoshimura M, Moriwaki K, Noto S, Takiguchi T (2017) A model-based cost-effectiveness analysis of osteoporosis screening and treatment strategy for postmenopausal Japanese women. Osteoporos Int 28(2):643–652. https://doi.org/10.1007/s00198-016-3782-5

29. Mori T, Crandall CJ, Ganz DA (2017) Cost-effectiveness of denosumab versus oral alendronate for elderly osteoporotic women in Japan. Osteoporos Int 28(5):1733–1744. https://doi.org/10.1007/s00198-017-3940-4

30. Moriwaki K, Mouri M, Hagino H (2017) Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan. Osteoporos Int 28(6):1939–1950. https://doi.org/10.1007/s00198-017-3973-8

31. Yoshizawa T, Nishino T, Okubo I, Yamazaki M (2018) Cost-effectiveness analysis of drugs for osteoporosis treatment in elderly Japanese women at high risk of fragility fractures: comparison of denosumab and weekly alendronate. Arch Osteoporos 13(1):94. https://doi.org/10.1007/s11657-018-0509-6

32. Moriwaki K, Fukuda H (2019) Cost-effectiveness of implementing guidelines for the treatment of glucocorticoid-induced osteoporosis in Japan. Osteoporos Int 30(2):299–310. https://doi.org/10.1007/s00198-018-4798-9

33. Kato G, Kurachi Y (2020) Cost-effective analysis of exercise programs designed for fall. Prevention among healthy younger old community-dwelling. Adults (Japanese). J Jpn Phys Ther Assoc 47(5):420–430. https://doi.org/10.15063/rigaku.11734

34. Hagino H, Tanaka K, Silverman S, McClung M, Gandra SR, Charokopou M, Adachi K, Johnson B, Stollenwerk B (2021) Cost-effectiveness of Romosozumab versus teriparatide for severe postmenopausal osteoporosis in Japan. Osteoporos Int 32(10):2011–2021. https://doi.org/10.1007/s00198-021-05927-1

35. Mori T, Crandall CJ, Fujii T, Ganz DA (2021) Cost-effectiveness of sequential daily teriparatide/weekly alendronate compared with alendronate monotherapy for older osteoporotic women with prior vertebral fracture in Japan. Arch Osteoporos 16(1):72. https://doi.org/10.1007/s11657-021-00891-z

36. Mori T, Crandall CJ, Fujii T, Ganz DA (2021) Cost-effectiveness of zoledronic acid compared with sequential denosumab/ alendronate for older osteoporotic women in Japan. Arch Osteoporos 16(1):113. https://doi.org/10.1007/s11657-021-00956-z

37. Takura T, Yuasa A, Nomioka N, Demiya S, Matsuda H, Ebata N, Fujii K, Ishijima M (2021) Cost-effectiveness analysis of the treatment strategies with or without opioid medications in surgery-eligible patients with osteoarthritis in Japan. Pharmacoecon Open 6:33–45. https://doi.org/10.1007/s41699-021-00292-5

38. Ota T, Harada A, Tokuda H (2002) Cost-effectiveness of hip fracture in Japan (Japanese). Nihon Ronen Igakkai Zasshi 39(5):483–488. https://doi.org/10.3143/geriatrics.39.483

39. Japanese Ministry of Health, Labour and Welfare (2017) Overview of national healthcare expenditures in fiscal year 2015. www.mhlw.go.jp/toukei/saikin/hk-iroyahi/15/dl/toukei_h27.pdf. Accessed 28 Dec 2021
40. Japanese Ministry of Health, Labour and Welfare various information of medical fee (Japanese). https://shinryohoshu.mhlw.go.jp/shinryohoshu/. Accessed 28 Dec 2021
41. Japanese Ministry of Health, Labour and Welfare (2017) Analysis of regional differences in healthcare costs in 2015 (Japanese). https://www.mhlw.go.jp/file/06-Seisakujouhou-12400000-Hokenkyoku/217iryohi.pdf. Accessed 28 Dec 2021
42. Takusari E, Sakata K, Hashimoto T, Fukushima Y, Nakamura T, Orimo H (2021) Trends in hip fracture incidence in Japan: estimates based on nationwide hip fracture surveys from 1992 to 2017. JBMR Plus 5(2):e10428. https://doi.org/10.1002/jbmr4.10428
43. Hasegawa M, Komoto S, Shiroiwa T, Fukuda T (2020) Formal implementation of cost-effectiveness evaluations in Japan: a unique health technology assessment system. Value Health 23(1):43–51. https://doi.org/10.1016/j.val.2019.10.005

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Authors and Affiliations

Takahiro Mori1,2,3 · Jun Komiyama4 · Tomoko Fujii1,4 · Masaru Sanuki5 · Keitaro Kume6 · Genta Kato7 · Yukiko Mori8 · Hiroaki Ueshima8 · Hiroki Matsui9 · Nanako Tamiya1,10 · Takehiro Sugiyama1,10,11

1 Health Services Research and Development Center, University of Tsukuba, 1-1-1 Tenno-dai, Tsukuba, Ibaraki 305-8575, Japan
2 Department of General Medical Science, Graduate School of Medicine, Chiba University, Chiba, Chiba, Japan
3 Department of General Internal Medicine, Eastern Chiba Medical Center, Togane, Chiba, Japan
4 Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Ibaraki, Japan
5 Department of Medical Research and Management for Musculoskeletal Pain, 22nd Century Medical & Research Center, The University of Tokyo Hospital, Tokyo, Japan
6 Department of Clinical Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan
7 Solutions Center for Health Insurance Claims, Kyoto University Hospital, Kyoto, Japan
8 Division of Medical Information Technology and Administration Planning, Kyoto University Hospital, Kyoto, Japan
9 Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan
10 Department of Health Services Research, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan
11 Diabetes and Metabolism Information Center, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan